Name: Quan-Wen Liu
Title: Associate Researcher
Email: liuquanwen@ncu.edu.cn
Place of Origin: Yichun, Jiangxi, China
Mentor Qualification: Master’s Supervisor
Courses Taught: Biopharmaceuticals, Drug Toxicology
Research Interests
1. Deciphering organ development and disease mechanisms using organoid models, and conducting organoid-based high-throughput drug screening.
2. Investigating the therapeutic potential and molecular mechanisms of mesenchymal stem cells-particularly human amniotic mesenchymal stem cells and human urine-derived stem cells-and their extracellular vesicles in major liver and kidney diseases.
Educational Background
2011.09 – 2014.09
Ph.D., Cell Biology, College of Life Sciences, Zhejiang University
Professional Experience
2024.12-Present
Associate Researcher, School of Pharmacy, Nanchang University
2020.12-2024.12
Associate Researcher, Institute of Translational Medicine, Nanchang University
2014.10-2020.12
Assistant Researcher, Institute of Translational Medicine, Nanchang University
Academic Service
1. Executive Member, Basic Pharmacology Committee, Jiangxi Pharmaceutical Association.
2. Member, Youth Working Committee, Jiangxi Society for Cell Biology.
3. Member, Chinese Society for Cell Biology.
4. Reviewer for multiple journals including Stem Cells International, International Journal of Molecular Sciences, Cell & Bioscience, etc.
Major Achievements
I. Research Funding
Principal investigator of more than 10 research projects, including two National Natural Science Foundation of China (NSFC) grants, one Jiangxi “Double Thousand Plan-High-Level Young Innovative Talent” project, one Jiangxi Provincial Distinguished Youth Fund project, one Jiangxi Natural Science Foundation Key Project, and several other provincial and horizontal projects. Total awarded funding exceeds 3 million RMB.
1. Projects as Principal Investigator
1. Enterprise-funded Project: Physicochemical characterization, cytotoxicity, and immune safety evaluation of biological amnion materials, 2025.06.01-2027.05.31, 200,000 RMB, Ongoing, Principal Investigator.
2. Jiangxi Provincial Department of Science and Technology, 2025 Key R&D Program (Social Development): Development of human decellularized amniotic membrane/antibacterial polyphenol composite dressing for burn wound repair (Project No. 2025BCG330018, 2025.01.01-2027.12.31), 1.2 million RMB, Co-Principal Investigator (Allocated: 300,000 RMB).
3. Jiangxi Provincial Natural Science Foundation-General Program: The effect and mechanism of human amniotic mesenchymal stem cells in improving the efficiency of islet transplantation by forming organoids (Project No. 20232BAB206040, 2023.07-2025.06), 100,000 RMB, ongoing, Principal Investigator.
4. Jiangxi Provincial Natural Science Foundation-Key Project: human amniotic mesenchymal stem cell derived exosomes miR-221-3p attenuate pulmonary fibrosis by blocking classical Wnt signaling pathways (Project No. 20224ACB206031, 2023.01-2025.12), 200,000 RMB, ongoing, Principal Investigator.
5. National Natural Science Foundation of China (NSFC): The effect and mechanism of human urine stem cell-derived exosomes in the treatment of premature ovarian failure via miRNA-21-5p (Project No. 82160285, 2022.01-2025.12), 340,000 RMB, ongoing, Principal Investigator.
6. Interdisciplinary Innovation Fund, Nanchang University-General Program: Specific analysis of menstrual blood-derived stem cell extracellular vesicles (MenSCs-Exo) and their molecular mechanisms in treating premature ovarian failure (POF) (Project No. 9167-28220007-YB2103, 2022.01-2023.12), 50,000 RMB, completed, Principal Investigator.
7. Chongqing Natural Science Foundation-General Program: Potential and mechanism by which hAMSC-derived extracellular vesicles inhibit pulmonary fibrosis through the delivery of miR-146a-5p (Project No. CSTB2022NSCQ-MSX1339, 2022.08–2024.07), 100,000 RMB, completed, Principal Investigator.
8. Jiangxi “Double Thousand Plan”-Young High-Level Innovative Talent Program: Potential and mechanism by which human amniotic mesenchymal stem cells (hAMSCs) ameliorate hyperglycemia in type 2 diabetic mice through regulating hepatic insulin resistance (Project No. jxsq2019201093, 2020.01–2022.12), 1,000,000 RMB, completed, Principal Investigator.
9. Jiangxi Provincial Natural Science Foundation-General Program: The effect and mechanism of human amniotic membrane mesenchymal stem cells on promoting β cell regeneration in type 1 diabetic mice (Project No. 20192BAB205032, 2019.01-2020.12), 60,000 RMB, completed, Principal Investigator.
10. National Natural Science Foundation of China (NSFC): The effect and mechanism of human amniotic membrane stem cells on amelioration of liver fibrosis by regulating the activation and proliferation of hepatic stellate cells (Project No. 81760118, 2018.01-2021.12), 340,000 RMB, completed, Principal Investigator.
11. Jiangxi Provincial Distinguished Youth Science Foundation: The mechanism of human amniotic membrane stem cells on inhibition of hepatocellular carcinoma by regulating of Wnt signaling pathway (Project No. 2018ACB21043, 2018.01–2021.12), 200,000 RMB, completed, Principal Investigator.
II. Representative Publications (Selected)
1. Jie-Zhou#，Ya-Yi Lin#，Wei-Fen Cheng，Xi-Yan Wang，Zi-Wei Chen，Xin-Yi Jiang，Shao-Bo Li，Xiang-Cheng Zhang，Ling-Fei Yan，Lin-Xie，Jing-Yuan Li*，Quan-Wen Liu*(Corresponding author). Human urine-derived stem cells from different donor sources ameliorate diabetic nephropathy in mice by activating autophagy and restoring mitochondrial function of podocyte. Life. Sci. 2025 Jul 1:378:123831. (JCR分区：Q1，IF=5.3).
2. Jia-Xin Zhou#, Jie-Zhou#, Wei-Ran Jin, Jing-Yuan Li, Xiang-Cheng Zhang, Chu-Yu Zhao, Ya-Yi Lin, Xi-Yan Wang, Ling-Fei Yan, Kai-Yan, Quan-Wen Liu*(Corresponding author). Human amniotic mesenchymal stem cell-islet organoids enhance the efficiency of islet engraftment in a mouse diabetes model. Life. Sci. 2024 Aug 15:351:12281. (JCR分区：Q1，IF=6.1)
3. Quan-Wen Liu# (First Author), Yan‐Min Ying, Jia‐Xin Zhou, Wen‐Jie Zhang, Zhao‐xiao Liu, Bing‐Bing Jia, Hao‐Cheng Gu, Chu‐Yu Zhao, Xiao‐Hui Guan, Ke‐Yu*, Deng and Hong‐Bo Xin*. Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt/β-catenin signaling pathway in mice. Stem Cell Res Ther. 2022. 13(1) :224. (JCR: Q1，IF: 8.079).
4. Quan-Wen Liu# (First Author), Qian-Yu Liu, Jing-Yuan Li, Li Wei, Kang-Kang Ren, Xiang-Cheng Zhang, Ting Ding, Ling Xiao, Wen-Jie Zhang, Han-You Wu, Hong-Bo Xin*. Therapeutic efficiency of human amniotic epithelial stem cell-derived functional hepatocyte-like cells in mice with acute hepatic failure. Stem Cell Res Ther. 2018; 9(1): 321. (JCR:Q1，IF: 8.079).
5. Jing-Yuan Li#, Kang-Kang Ren, Wen-Jie Zhang, Ling Xiao, Han-You Wu, Qian-Yu Liu, Ting Ding, Xiang-Cheng Zhang, Wen-Jia Nie, Yu Ke, Ke-Yu Deng, Quan-Wen Liu*(Co-corresponding author), Hong-Bo Xin*. Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cells apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway. Stem Cell Res Ther. 2019; 10(1): 247. (JCR：Q1，IF: 8.079).
6. Quan-Wen Liu# (First Author), Qi-Ming Huang, Han-You Wu, Guo-Si-Lang Zuo, Hao-Cheng Gu, Ke-Yu Deng, Hong-Bo Xin*. Characteristics and therapeutic potential of human amnion-derived stem cells. Int J Mol Sci. 2021; 22: 970. (JCR: Q1，IF: 6.208).
7. Quan-Wen Liu# (First Author), Yong Chen, Jing-Yuan Li, Ling Xiao, Wen-Jie Zhang, Jia-Le Zhao, Hao-Cheng Gu, Han-You Wu, Guo-Si-Lang Zuo, Ke-Yu Deng*, and Hong-Bo Xin*. Bone marrow cells are differentiated into MDSCs by BCC-Ex through down-regulating the expression of CXCR4 and activating STAT3 signaling pathway. J Cell Mol Med. 2021; 25(12): 5497-5510. (JCR:Q2，IF: 5.295).
8. Han-You Wu #, Xiang-Cheng Zhang #, Bing-Bing Jia, Ye Cao, Kai-Yan, Jing-Yuan Li, Li-Tao, Zhi-Gang Jie, Quan-wen Liu*(Corresponding author).. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acetaminophen-induced acute liver failure through activating ERK and IGF-1R/PI3K/AKT signaling pathway. J Pharmacol Sci. 2021; 147(1): 143-155. (JCR: Q2，IF: 3.578).
9. Quan-Wen Liu# (First Author), Jing-Yuan Li, Xiang-Cheng Zhang, Yu Liu, Qian-Yu Liu, Ling Xiao, Wen-Jie Zhang, Han-You Wu, Ke-Yu Deng*, Hong-Bo Xin*. Human amniotic mesenchymal stem cells inhibit hepatocellular carcinoma in tumor-bearing mice. J Cell Mol Med. 2020; 24 (18): 10525-10541. (JCR: Q2，IF: 5.295).
10. Qian-Yu Liu#, Feng Ruan, Jingyuan Li, Li Wei, Ping Hu, Houwen Chen, Quan-wen Liu*(Corresponding author). Human Menstrual Blood-Derived Stem Cells Inhibit proliferation of Hela cells via TGF-β1 mediated JNK/P21 signaling pathways. Stem Cells Int. 2019: 9280298. (JCR: Q2，IF:5.131).
III. Patents
1. A marker and application for detecting mouse inner ear stem cells, China Patent No. ZL201410495125.6, Granted: 2017.01.25.
2. A marker and application for detecting mouse inner ear hair cells. China Patent No. ZL201410493237.8, Granted: 2017.02.24.
3. A marker and application for detecting mouse inner ear progenitor cells, China Patent No. ZL201410495359.0, Granted: 2017.02.24.
4. A method for inducing human amniotic epithelial stem cells into functional hepatocytes, China Patent No. ZL201810857098.0, Granted: 2021.06.10.
Cn
